PDF(Pubmed)
Abstract：
Treatment of wrinkles and dynamic lines with botulinum toxin has been a routine practice for years in aesthetic clinical settings. The effective treatment of wrinkles requires a comprehensive understanding of facial expression muscles and their interactions, the mechanism of action of botulinum toxin, and individual patient preferences. The dose adjustment practice and injection technique of physicians are affected by cultural differences; most Asian patients prefer natural-looking results. This article aims to present an expert consensus on the injection sites, doses, and levels of botulinum toxin for various indications in Asians, with the hope of providing guidance to some clinicians. This consensus paper reviews LetibotulinumtoxinA for patient evaluation, dosage, and delivery techniques in Asians from the time LetibotulinumtoxinA was approved up to December 2022. Panelists proposed individualized treatment plans for botulinum toxin type A (BTxA) treatments in 3 areas-wrinkle removal, contour adjustment, and face lifting-for Asians based on their extensive experience and knowledge of facial anatomy. When using a different BTxA, clinicians should start with a conservative dose and carefully individualize the treatment for each patient, and adjust it according to feedback to obtain a higher satisfaction level.
摘要：
使用肉毒杆菌毒素治疗皱纹和动态线条多年来一直是美学临床环境中的常规实践。有效治疗皱纹需要全面了解面部表情肌肉及其相互作用，肉毒杆菌毒素的作用机制，和患者个人偏好。医生的剂量调整实践和注射技术受到文化差异的影响；大多数亚洲患者更喜欢自然的结果。本文旨在就注射部位提出专家共识，剂量,以及亚洲人各种适应症的肉毒杆菌毒素水平，希望为一些临床医生提供指导。这篇共识论文回顾了LetibotulinumtoxinA(Letybo，HugelPharmaInc.,首尔,韩国）用于患者评估，剂量,从LetibotulinumtoxinA被批准到2022年12月，亚洲人的交付技术。小组成员在去除皱纹的三个方面提出了A型肉毒杆菌毒素（BTxA）的个体化治疗计划，轮廓调整,根据亚洲人的丰富经验和面部解剖结构进行面部矫正。当使用不同的BTxA时，临床医生应该从保守剂量开始，并为每个患者仔细个性化治疗，并根据反馈进行调整，以获得更高的满意度。
